You’ve probably seen the headlines. Celebrity weight loss transformations. TikTok before-and-afters. Your coworker who suddenly dropped three sizes and gets weirdly quiet when you ask how.
Behind most of these stories are two medications: semaglutide (sold as Ozempic and Wegovy) and tirzepatide (sold as Mounjaro and Zepbound). Both are injectable peptides originally developed for type 2 diabetes. Both have become cultural phenomena for weight loss.
But here’s what most articles won’t tell you: these two drugs work differently at a fundamental level. Not just “one is stronger than the other” different. Actually mechanistically different.
So which one are people losing more weight on? Let’s look at what the evidence actually shows, not what the marketing wants you to believe.
What’s actually happening in your body with each one?
Semaglutide mimics a hormone called GLP-1 (glucagon-like peptide-1). Your gut naturally releases GLP-1 when you eat. It tells your pancreas to release insulin, slows down your stomach emptying, and sends signals to your brain that you’re full.
Semaglutide is basically a supercharged, long-lasting version of this hormone. Instead of GLP-1 breaking down in minutes, semaglutide sticks around for about a week. That’s why it’s a once-weekly injection.
Tirzepatide does something more complex. It mimics two hormones: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual action is why you’ll sometimes hear it called a “twincretin.”
The honest answer about why this matters is that we’re still figuring it out. GIP’s role in weight loss is surprisingly murky. Some researchers thought GIP might actually promote fat storage. But in combination with GLP-1, something different happens. The two hormones together seem to amplify effects on appetite, blood sugar, and metabolism in ways we don’t fully understand yet.
Think of it like this: semaglutide is hitting one target really well. Tirzepatide is hitting two targets, and they seem to work better together than either would alone.
What the clinical trials actually found
Let’s talk numbers, because this is where things get interesting.
The STEP trials studied semaglutide for weight loss. At the highest dose (2.4mg weekly), people lost an average of about 15% of their body weight over 68 weeks. For someone starting at 220 pounds, that’s roughly 33 pounds.
The SURMOUNT trials studied tirzepatide. At the highest dose (15mg weekly), people lost an average of about 21% of their body weight over 72 weeks. For that same 220-pound person, that’s about 46 pounds.
That’s a meaningful difference. About 6 percentage points more weight loss with tirzepatide at maximum doses.
But here’s what those headline numbers don’t capture.
First, not everyone takes the maximum dose. Side effects (mostly nausea, vomiting, and digestive issues) push many people to stay at lower doses. At lower doses, the gap between the two drugs narrows.
Second, these were different trials with different participants. They weren’t head-to-head comparisons. The people who enrolled in STEP trials weren’t the same population as SURMOUNT trials. Their starting weights, health conditions, and other factors varied.
Third, averages hide enormous individual variation. Some people on semaglutide lost 25% of their body weight. Some people on tirzepatide lost 8%. Your response depends on factors we can’t fully predict yet, including genetics, gut microbiome, baseline metabolic health, and lifestyle factors.
The side effect conversation nobody wants to have
Both medications come with gastrointestinal side effects. Nausea, vomiting, diarrhea, constipation. These are extremely common, especially when starting or increasing doses.
The honest answer about which one is “easier” to tolerate is that it varies wildly by person. Some people breeze through semaglutide with minor nausea. Others can’t get past the starting dose of tirzepatide without severe stomach issues.
In clinical trials, tirzepatide at higher doses showed slightly higher rates of nausea and vomiting compared to semaglutide. But “slightly higher in a trial” doesn’t predict what will happen in your body.
What we don’t know yet is whether the dual-hormone approach of tirzepatide creates meaningfully different side effect patterns over the long term. Both drugs are relatively new. We have a few years of widespread use for semaglutide, less for tirzepatide.
There are also questions about muscle loss. Rapid weight loss from any method tends to include some muscle mass, not just fat. Some researchers are concerned that GLP-1 medications may cause more muscle loss than traditional weight loss approaches. The data here is still emerging.
And then there’s what happens when you stop. Studies following people who discontinued semaglutide showed most regained a significant portion of the weight within a year. We don’t have equivalent long-term discontinuation data for tirzepatide yet, but there’s no biological reason to expect it would be different.
The cost and access reality
Here’s where things get frustrating.
Both medications are expensive without insurance. We’re talking $1,000+ per month retail price. Insurance coverage is inconsistent and often requires jumping through hoops like prior authorizations and documented diet attempts.
Semaglutide has been around longer, so there’s slightly more insurance infrastructure around it. Tirzepatide is newer and some insurers haven’t figured out their coverage policies yet.
Compounding pharmacies have started offering versions of both peptides at lower prices. This is a legally gray area that’s currently under scrutiny. The FDA has expressed concerns about compounded versions. If you’re considering this route, understand that quality control varies significantly between compounding pharmacies, and you’re operating outside the FDA-approved system.
So which one should you actually consider?
If you’re reading this hoping I’ll tell you “take this one,” I’m going to disappoint you.
The honest answer is that tirzepatide appears to produce more weight loss on average at maximum doses. The dual-hormone mechanism seems to offer something additional beyond what GLP-1 alone provides.
But averages aren’t destiny. Your response to either medication depends on factors specific to your body. And the “best” weight loss medication is the one you can actually access, afford, tolerate, and sustain.
Some practical considerations:
If you have type 2 diabetes, both medications are FDA-approved for glycemic control, and both show strong results. Your doctor may have preferences based on your specific diabetes management needs.
If weight loss is your primary goal, tirzepatide’s data looks more impressive on paper. But semaglutide has a longer track record and more post-market data about what happens with extended use.
If cost is a major factor, neither is cheap, but semaglutide’s slightly longer market presence might mean more options for patient assistance programs or insurance appeals.
If you’ve tried one and it didn’t work, that’s useful information. Some people who don’t respond well to semaglutide do better on tirzepatide, and vice versa. We don’t fully understand why yet.
What we’re still waiting to learn
Both of these medications represent genuine advances in obesity treatment. For people who have struggled with weight despite genuine effort, they offer something that wasn’t available before.
But we’re early in understanding them.
We don’t know the truly long-term effects of taking these medications for decades. Most studies run 1 to 2 years. What happens at year 10?
We don’t fully understand who responds best to which medication. Personalized medicine would let us predict this, but we’re not there yet.
We don’t know the optimal way to transition off these medications while maintaining weight loss, or if that’s even reliably possible.
And we don’t know how these medications interact with aging, menopause, other health conditions, or the dozens of other variables that affect metabolism.
Your actual next step
If you’re considering either medication, start with a conversation with a doctor who actually understands metabolic health. Not a quick telehealth visit designed to approve prescriptions, but a real assessment of your health history, goals, and risk factors.
Ask specifically about how each medication might interact with any conditions you have. Ask about realistic expectations for your situation. Ask what the plan is if side effects become unmanageable.
And be honest with yourself about sustainability. These medications work while you take them. They’re not a six-month fix. If you can’t see yourself affording, accessing, and tolerating weekly injections indefinitely, factor that into your decision.
The weight loss space is full of hype. Semaglutide and tirzepatide are legitimately effective, but they’re medical tools with tradeoffs, not magic. Treat them that way.